Davis Timothy M E, Chubb S A Paul, Davis Wendy A
School of Medicine and PharmacologyUniversity of Western Australia, Fremantle, Western Australia, Australia
School of Medicine and PharmacologyUniversity of Western Australia, Fremantle, Western Australia, Australia Department of Clinical BiochemistryPathWest Laboratory Medicine WA, Perth, Western Australia, Australia School of Pathology and Laboratory MedicineUniversity of Western Australia, Nedlands, Western Australia, Australia.
Eur J Endocrinol. 2016 Oct;175(4):273-85. doi: 10.1530/EJE-16-0327. Epub 2016 Jul 14.
To investigate the association between estimated GFR (eGFR) and all-cause mortality, including the contribution of temporal eGFR changes, in well-characterised community-based patients with type 2 diabetes.
Longitudinal observational study.
Participants from the Fremantle Diabetes Study Phase 1 were assessed between 1993 and 1996 and followed until end-December 2012. Cox proportional hazards modelling was used to assess the relationship between baseline eGFR category (Stage 1-5) and all-cause death, and between eGFR trajectories assigned by semiparametric group-based modelling (GBM) and all-cause death in patients with five post-baseline annual eGFR measurements.
In the full cohort (1296 patients; mean±s.d. age 64.1±11.3years, 48.6% males), 738 (56.9%) died during 12.9±6.1years of follow-up. There was a U-shaped relationship between all-cause death and eGFR category. With Stage 3 (45-59mL/min/1.73m(2)) as reference, the strongest association was for eGFR ≥90mL/min/1.73m(2) (hazard ratio (95% CI) 2.01 (1.52-2.66); P<0.001). GBM identified four linear trajectories ('low', 'medium', 'high', 'high/declining') in 532 patients with serial eGFR measurements. With medium trajectory as reference, eGFR trajectory displaced baseline eGFR category as an independent predictor of death, with low and high/declining trajectories associated with more than double the risk (2.03 (1.30-3.18) and 2.24 (1.31-3.83) respectively, P≤0.003) and associated median reductions in survival of 6.5 and 8.7years respectively.
There is a nonlinear relationship between eGFR and death in type 2 diabetes, which is at least partially explained by a sub-group of patients with an initially high but then rapidly declining eGFR.
在特征明确的社区2型糖尿病患者中,研究估算肾小球滤过率(eGFR)与全因死亡率之间的关联,包括eGFR随时间变化的影响。
纵向观察性研究。
对弗里曼特尔糖尿病研究第一阶段的参与者在1993年至1996年期间进行评估,并随访至2012年12月底。采用Cox比例风险模型评估基线eGFR类别(1-5期)与全因死亡之间的关系,以及在有五次基线后年度eGFR测量值的患者中,基于半参数分组建模(GBM)分配的eGFR轨迹与全因死亡之间的关系。
在整个队列(1296例患者;平均±标准差年龄64.1±11.3岁,48.6%为男性)中,738例(56.9%)在12.9±6.1年的随访期间死亡。全因死亡与eGFR类别之间呈U形关系。以3期(45-59mL/min/1.73m²)为参照,最强的关联是eGFR≥90mL/min/1.73m²(风险比(95%CI)2.01(1.52-2.66);P<0.001)。GBM在532例有连续eGFR测量值的患者中确定了四条线性轨迹(“低”、“中”、“高”、“高/下降”)。以中轨迹为参照,eGFR轨迹取代基线eGFR类别成为死亡的独立预测因素,低轨迹和高/下降轨迹的风险增加一倍以上(分别为2.03(1.30-3.18)和2.24(1.31-3.83),P≤0.003),且生存中位数分别减少6.5年和8.7年。
2型糖尿病患者中eGFR与死亡之间存在非线性关系,这至少部分可由一组初始eGFR高但随后迅速下降的患者来解释。